

Swedencare AB (publ) Communiqué from the Extraordinary General Meeting 2022

At Swedencare's Extraordinary General Meeting, which was held in Malmö on January 18, 2022, the following decisions were made.

Decision on the introduction of an incentive program for employees, including a directed issue of warrants

The proposal was supported by 81.55% of the votes and shares represented at the meeting, while 18.45% voted against the proposal. As the proposal requires at least nine tenths, the Extraordinary General Meeting decided not to adopt the proposed incentive program.

Authorization to the board of directors to issue new shares

The Extraordinary general meeting authorized the board of directors to, whether on one or several occasions for the period up to the next annual meeting of shareholders, to increase the company's share capital with not more than SEK 400 000 by an issue of not more than 40 000 000 new shares. The Board of Directors shall be authorised to adopt decisions on an issue of shares with deviation from the shareholders' pre-emption rights and/or an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to in Chapter 2, Section 5, second paragraph, points 1-3 and 5, of the Swedish Companies Act.

An issue in accordance with this authorization shall be on market conditions, and where applicable be subject to issue discount at market rate. The Board of Directors shall be authorised to decide on the terms and conditions regarding issues under this authorisation and what persons shall be entitled to subscribe for the shares. The reason to propose that the Board of Directors shall be authorised to resolve on an issue with deviation from the shareholders' pre-emption rights and that the board shall be authorised to decide on an issue in kind or an issue by way of set-off or otherwise on such terms and conditions as referred to above is that the company shall be able to issue shares in order to enable financing of the business and/or acquisition of all or parts of companies, businesses and/or product and trademark rights.

For more information, please contact:

Håkan Lagerberg, CEO Swedencare
Phone: +46 (0)73 517 01 70
Email: hakan.lagerberg@swedencare.se

Jenny Graflind, CFO Swedencare
Phone: +46 (0)73 944 85 54
Email: jenny.graflind@swedencare.se

FNCA is the Certified Adviser of the Company
Phone: +46 (0) 8 528 00 399
Email: info@fnca.se

Please visit the Company homepage www.swedencare.com

About Swedencare

Swedencare, a listed company on NASDAQ First North Growth Market, specializes in pet healthcare and produces, markets and sells premium products in the global and fast-growing market. The company has a wide range of strong brands and products within most therapy areas, including Animal Pharmaceuticals®, nutravet®, NutriScience, Pet MD®, Stratford®, VetWELL® as well as ProDen PlaqueOff® for oral health to dogs and cats. Swedencare's headquarter is in Malmö, Sweden with subsidiaries located in eight countries with products sold in approximately fifty markets. Swedencare's sales have increased significantly over the last few years with strong margins and profits.

Attachments

[Swedencare AB \(publ\) Communiqué from the Extraordinary General Meeting 2022](#)